scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that have the potential to support the delivery of infused therapies and patient care. Co.'s main product candidate, FUROSCIX, consists of its buffered formulation of furosemide delivered subcutaneously via an on-body infusor and is under development for treatment of congestion in patients with worsening heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Co. has filed an investigational new drug application for scCeftriaxone, an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. The SCPH stock yearly return is shown above.
The yearly return on the SCPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SCPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|